Targeted Therapies
Avalo is a clinical stage biotechnology company focused on the treatment of immune dysregulation.
Avalo is a clinical stage biotechnology company focused on the treatment of immune dysregulation.
Avalo is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo also has two additional drug candidates, which include quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
View PipelineWe share a commitment to teamwork, passion for science, and dedication to patients suffering from acute and chronic inflammatory disorders. Our cross-functional team has a deep understanding of disease pathology and clinical development of novel therapeutic targets. Our collective expertise in discovery, development, and regulatory approvals is evidenced in our strong individual track records of advancing multiple therapeutic programs to successful commercialization.
View Leadership Team